
==== Front
ACS OmegaACS OmegaaoacsodfACS Omega2470-1343American Chemical Society 3145936110.1021/acsomega.8b02916ArticleDirect Functionalization of C(sp2)–H
Bond in Nonaromatic Azaheterocycles: Palladium-Catalyzed Cross-Dehydrogenative
Coupling (CDC) of 2H-Imidazole 1-Oxides
with Pyrroles and Thiophenes Akulov Alexey
A. †Varaksin Mikhail V. †‡Charushin Valery N. †‡Chupakhin Oleg N. *†‡† Department
of Organic & Biomolecular Chemistry, Ural Federal University, 19 Mira Street, 620002 Ekaterinburg, Russia‡ Institute
of Organic Synthesis, Ural Branch of the
Russian Academy of Sciences, 22 S. Kovalevskaya Street, 620041 Ekaterinburg, Russia* E-mail: chupakhin@ios.uran.ru.10 01 2019 31 01 2019 4 1 825 834 26 10 2018 26 12 2018 Copyright © 2019 American Chemical
Society2019American Chemical
SocietyThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

The C(sp2)–H bond
functionalization methodology
was first applied to carry out the palladium-catalyzed oxidative C–H/C–H
coupling reactions of 2H-imidazole 1-oxides with
pyrroles and thiophenes. As a result, a number of novel 5-heteroarylated
2H-imidazole 1-oxides, which are of particular interest
in the design of bioactive molecules and advanced materials, have
been synthesized in yields up to 78%. The detailed H/D-exchange experiments
have also been performed to elucidate some mechanistic features of
this cross-dehydrogenative coupling process.

document-id-old-9ao8b02916document-id-new-14ao-2018-02916xccc-price
==== Body
Introduction
Many organic compounds
bearing the N-oxide structural motif are
known as promising building blocks in the design of advanced materials,
agrochemicals, cosmetics, and pharmaceuticals.1 The prevalence of the N-oxide scaffold in prospective organic compounds
seems to be associated with the specific changes in properties of
heterocyclic N-oxides relative to their parent compounds.2 Currently, this distinguishing feature of the
N+–O– motif is often used in retrosynthetic
schemes as an elegant tool to induce the desired physical and chemical
properties, as well as pharmacological activities and other beneficial
outcomes for the target compounds. In addition, the N-oxide function
is generally considered as one of the privileged scaffolds in the
structures of both intermediates and final products exhibiting a variety
of therapeutic effects, such as antibacterial, antiviral, anticancer,
antiprotozoal, antifungal, neuroprotective, and other activities.3

Among the known biologically active and
medicinally important compounds
bearing the N-oxide function, derivatives in which the −C=N+–O– pharmacophore fragment is partly
involved in a (hetero)aromatic ring (Figure 1) attract special attention. For instance,
chlordiazepoxide I is a sedative and hypnotic medication
of the benzodiazepine family, which is commonly used for the treatment
of anxiety, insomnia, and to withdraw symptoms from alcohol and/or
drug abuse.4 1,7-Naphthyridine N-oxide II, the p38α mitogen-activated
protein kinase inhibitor, is considered to be an efficient agent for
therapy of autoimmune and inflammatory diseases.5 Indoline derivative III shows neuroprotective
spin-trapping properties and prevents cell death under oxidative stress
conditions.3j Furoxane IV,
being a good nitric oxide donor, proved to possess an increased procognitive
activity and cytotoxicity.6 2,2′-Pyridylisatogen V is a good antioxidant agent with neuroprotective activity.7

Figure 1 Prospective N-oxide-based pharmaceuticals and drug candidates.

It is worth noting that an overwhelming
majority of practically
interested organic compounds have turned out to be bi- and/or polyfunctional
derivatives in which the structural subunits are linked to each other
through the carbon–carbon bonds.8 In this respect, one of the key challenges for modern organic synthesis
is the development of simple and convenient approaches to obtain the
target organic ensembles containing various functional building blocks
through the construction of the C–C bonds.9 The effectiveness and expediency of the methods used can
be easily assessed, taking into account the compliance of the latter
with the basic principles of green chemistry, such as atom and step
economy.10 Currently, the green chemistry-oriented
C–H functionalization methodology,11,12 which allows one to convert C(sp2)–H bonds of
the starting materials into C–C bonds of the target products
without any preliminary functionalization of the reactive partners,
is considered to be a useful synthetic tool because it provides the
environmental-friendly solutions in the design of bi- and/or polyfunctional
organic compounds of various architectures.

One of the most
promising approaches based on the C(sp2)–H functionalization
methodology suggests using the transition-metal-catalyzed
oxidative C–H/C–H coupling reactions between (hetero)arenes.8a,8b,12 These industrially important
processes, being atom- and stage-efficient alternative to both C–X/C–Y
and C–H/C–X(Y) coupling strategies [X = (pseudo)halide,
Y = metal], are actively used to functionalize aromatic and heteroaromatic
(π-excessive and π-deficient) compounds, including azine
N-oxides and other azine-activated forms. At the same time, the number
of C–H/C–H coupling reactions studied in the chemistry
of nonaromatic nitrogen-containing compounds has still rather been
limited. Indeed, a few examples of the direct C–H functionalization
of cyclic aldonitrones lacking an aromatic π-conjugated system
are presented by the following reactions of 2H-imidazole
1-oxides: uncatalyzed by transition metals (i) oxidative C–H/C–Li
coupling with organometallics,13 (ii) metalation
followed by coupling with electrophiles,14 (iii) eliminative C–H/C–H coupling with azoles,15 and (iv) Pd(II)-catalyzed
oxidative C–H/C–H coupling with indoles.15b It should be noted that in case of oxidative
reactions (i, ii, and iv), the retention of the N-oxide group in the
coupling products is observed, whereas the eliminative process (iii)
has been shown to result in the formation of 2H-imidazoles
with the loss of the N-oxide function.

This study is aimed at
the development of a facile and effective
synthetic approach for the direct C(sp2)–H bond
functionalization of cyclic aldonitrones with fragments of pyrroles
and thiophenes to obtain novel heterocyclic ensembles, 5-heteroaryl-substituted
2H-imidazole 1-oxides, in good yields.

Results and Discussion
The methodology for the direct nucleophilic C(sp2)–H
bond functionalization in the series of nonaromatic 2H-imidazole 1-oxides 1 has first been used as the main
synthetic strategy to the family of novel C(5)-modified 2H-imidazole derivatives. In particular, the Pd(II)-mediated C–H/C–H
cross-coupling reactions of cyclic nitrones 1a–c with a variety of π-excessive pyrroles and thiophenes 2a–g bearing both electron-donating and electron-withdrawing
substituents have been carried out. The elaborated cross-dehydrogenative
C–C coupling reactions have been shown to result in the formation
of previously unknown biheterocyclic ensembles containing the N-oxide
group in the imidazole ring in 40–78% yields (Table 1).

Table 1 Scope and
Yields for the Pd(II)-Mediated
Oxidative Cross-Coupling Reaction of 2H-Imidazole
1-Oxides 1a–c with Pyrroles and Thiophenes 2a–ga,b
a Reaction conditions:
2H-imidazole 1-oxides 1a–c (1
mmol), pyrroles and
thiophenes 2a–g (2 mmol), Pd(OAc)2 (0.1
mmol), Cu(OAc)2·H2O (1.5 mmol), and pyridine
(1.5 mmol) in 1,4-dioxane (5 mL) at 110–120 °C for 24
h.

b Isolated yields.

A special attention has been focused
on the conditions optimization
for these cross-coupling reactions by varying the basic parameters,
such as molar ratio of the coupling partners 1 and 2, amounts of catalyst Pd(OAc)2 and oxidant Cu(OAc)2, and the reaction time. Initially, the conditions that had
earlier been used for the direct C–H/C–H coupling of
aldonitrones with indoles were checked.15b,16 The interaction of aldonitrone 1b with thiophene 2b proceeding in 1,4-dioxane at 120 °C in the presence
of pyridine was chosen as the model reaction (Table 2). As a result of these experiments, the
best yield (75%) of the coupling product 3g, 5-(5-acetylthiophen-2-yl)-2-ethyl-2-methyl-4-phenyl-2H-imidazole 1-oxide, has been achieved after 24 h with the
following ratio of reagents (Table 2, entry 9): 2H-imidazole 1b (1 mmol), thiophene 2b (2 mmol), palladium (0.1 mmol)
and copper (1.5 mmol) acetates.

Table 2 Optimization of Conditions
for the
Palladium(II)-Catalyzed Oxidative Cross-Coupling Reaction of 2H-Imidazole 1-Oxide 1b with Thiophene 2b
entry	1b (mmol)	2b (mmol)	Pd(OAc)2 (mmol)	Cu(OAc)2·H2O (mmol)	reaction
time (h)	yield of 3g (%)	
1	1.0	1.0	0.02	1.0	2	36	
2	1.0	1.0	0.02	1.0	4	42	
3	1.0	1.0	0.02	1.0	8	45	
4	1.0	1.0	0.06	1.0	12	52	
5	1.0	1.0	0.1	1.0	24	58	
6	1.0	1.5	0.02	1.0	2	36	
7	1.0	2.0	0.06	1.0	12	54	
8	1.0	2.5	0.1	1.0	24	57	
9	1.0	2.0	0.1	1.5	24	75	
10	1.0	2.0	0.1	2.5	32	73	
11	1.0	0.5	0.1	1.5	24	72	
12	1.0	0.3	0.1	1.5	24	70	
In accordance with the modern
concept for transition-metal-catalyzed
cross-dehydrogenative coupling (CDC) reactions,17 the oxidative C–H/C–H coupling of 2H-imidazole 1-oxides with π-excessive heterocyclic
compounds, such as pyrroles or thiophenes, seems to be a cyclic redox
process. The organopalladium intermediates bearing the C–Pd
bond are supposed to be formed, and the cyclic redox transformations
of palladium catalyst Pd(II) → Pd(0) → Pd(II) take place
in this case. It should also be mentioned that the data of mechanistic
studies on these transition-metal-catalyzed cross-dehydrogenative
coupling reactions suggest two plausible ways for palladium-induced
activation of the C–H bond in (hetero)arenes, namely, electrophilic
aromatic metalation and concerted metalation–deprotonation
pathways.18

To gain insight into
the CDC reaction mechanism and elucidate the
competiveness for palladation of the reactive partners, the H/D exchange
experiments have been performed (Scheme 1) using NMR spectroscopy. Herein, the previously
described experimental protocol19 has been
applied to perform a series of experiments separately with 2H-imidazole 1-oxide 1a and 2-acetylthiophene 2b by using the standard conditions: Pd(OAc)2,
0.1 mmol; Cu(OAc)2·H2O, 1.5 mmol; 1,4-dioxane,
5 mL; heating at 110–120 °C for 24 h, and D2O, 20 mmol, as a deuterium source. The data of the 1H
NMR experiments performed are summarized in Table 3.

Scheme 1 H/D Exchange Experiments for Cross-Dehydrogenative
Coupling Partners 1a and 2b
Table 3 Conditions and Results of the H/D-Exchange
Control Experimentsa
 	 	 	conditions	 	 	
entry	1a (1.0 mmol)	2b (1.0 mmol)	Py (1.5 mmol)	Pd(OAc)2 (0.1 mmol)	Cu(OAc)2·H2O (1.5 mmol)	1a/1a-[D1] ratio	2b/2b-[D1] ratio	
1	+	–	–	+	+	1.00:0	–	
2	–	+	–	+	+	–	1.00:0	
3	+	–	+	+	+	1.00:0	–	
4	–	+	+	+	+	–	0.65:0.35	
5	–	+	+	–	+	–	1.00:0	
6	–	+	+	+	–	–	0.65:0.35	
a The resulted reaction
mixtures were
analyzed by 1H NMR spectroscopy in dimethyl sulfoxide (DMSO)-d6 at 295 K.

In the first instance, the role of pyridine in the
process has
been studied. The control experiments with compounds 1a and 2b carried out without pyridine have afforded no
deuterated products (Table 3, entries 1 and 2), thus showing the crucial role of pyridine
as a ligand in these transformations. Indeed, in analogous experiments
proceeding in the presence of pyridine the hydrogen–deuterium
exchange was shown to occur in case of 2-acetylthiophene 2b (Table 3, entries
3 and 4). Therefore, it has been suggested that the initial step of
the cross-coupling process under discussion is the formation of the
organopalladium intermediate derived from heteroaromatic compound 2 (pyrrole or thiophene) rather than from nitrone 1. To confirm this hypothesis, attempts to deuterate 2-acetylthiophene 2b in the absence of either palladium catalyst Pd(OAc)2 or oxidant Cu(OAc)2 have been undertaken. As expected,
no hydrogen–deuterium exchange has been found to be occur in
the absence of palladium acetate (Table 3, entry 5), whereas in the absence of copper
acetate, compound 2b was deuterated up to 35% (Table 3, entry 6). These
data appear to support the hypothesis that the covalent C–Pd
bond is formed at the first step of the cross-coupling process deriving
from the reaction of thiophene/pyrrole 2 with palladium
acetate. In addition, the experimental data obtained have enabled
us to refute the other versions of the hydrogen–deuterium exchange
process associated with acid–base interactions of 2 with pyridine. as well as with the formation of organocopper intermediates.
To illustrate it, the distinctive fragments of the 1H NMR
spectra of the reaction mixtures after furnishing the H/D-exchange
control experiments with 2-acetylthiophene 2b are shown
in Figure 2.

Figure 2 Fragments of the 1H NMR spectra of the resulted
reaction
mixtures for H/D-exchange control experiments in case of 2-acetylthiophene 2b in the absence (a) (Table 3, entry 2) and the presence (b) of pyridine (Table 3, entry 4).

On the basis of the experimental
results and the analysis of the
literature data,20,21 a plausible mechanism for the
described cross-coupling reactions has been advanced (Scheme 2). It suggests that the formation
of above-mentioned organopalladium intermediates A takes
place at the first step due to the interaction of heteroaromatic compounds 2a–g with palladium(II) and pyridine molecules, which
act as ligands (Ln) that stabilize the
organometallic intermediates.18 Intermediates A seem to be coordinated with the oxygen center of 2H-imidazole 1-oxides 1a–c through the
ligand-exchange mechanism to form intermediates B. The
chelate-controlled functionalization of the nitrone C(1)–H
bond through the concerted metalation/deprotonation transformations20b,21 appears to afford the intermediates C. Further reductive
elimination has likely to form the desired biheterocyclic products 3a–r and Pd(0). The latter can be transformed into
Pd(II) form via oxidation with copper(II) acetate, thus undergoing
the recycling process.

Scheme 2 Plausible Catalytic Cycle for the Cross-Dehydrogenative
Coupling
Reactions of 2H-Imidazole 1-Oxides 1a–c with Pyrroles and Thiophenes 2a–g
Conclusions
In
summary, an original atom- and step-economical approach based
on the palladium-mediated oxidative cross-dehydrogenative C–C
coupling reactions (CDC) has successfully been applied for the synthesis
of previously unknown biheterocyclic N-oxide ensembles. The mechanistic
features of the C–H activation process have been highlighted,
and the series of novel 5-heteroarylated 2H-imidazole
1-oxides, which are of particular interest in the design of bioactive
molecules and advanced materials, has been obtained and fully characterized.
The developed methodology proved to be an efficient synthetic tool
to provide C(sp2)–H/C(sp2)–H cross-coupling
of 2H-imidazole 1-oxides with π-excessive heterocyclic
compounds, such as pyrroles or thiophenes, affording the target products
in yields up to 78%.

Experimental Section
General Experimental Methods
The NMR (1H,
400 MHz and 13C, 100 MHz) spectra were recorded on a Bruker
AVANCE II spectrometer in DMSO-d6 using
tetramethylsilane as an internal standard. The 13C NMR
spectra were recorded in a mode of attached proton test with full
proton decoupling. The mass spectra (EI) were obtained by means of
a SHIMADZU GCMS-QP2010 Ultra mass spectrometer. The infrared spectra
were recorded on a Bruker Alpha FT-IR spectrometer. The elemental
analysis was fulfilled on a CHNS/O analyzer. The reactions course
was monitored by thin-layer chromatography (0.25 mm silica gel plates,
Merck 60F 254). Column chromatography was carried out on 220–440
mesh silica gel (60, 0.035–0.070 mm).

General Procedure for the
Synthesis of 3a–r
In a similar manner to the previously
described procedure,15b a mixture of aldonitrone 1a–c (1 mmol), pyrrole or thiophene 2a–g (2 mmol),
palladium(II) acetate (22.5 mg, 0.1 mmol), copper(II) acetate monohydrate
(300 mg, 1.5 mmol), and pyridine (0.12 mL, 1.5 mmol) in 1,4-dioxane
(5 mL) was refluxed at 110–120 °C for 24 h. The cooled
to ambient temperature reaction mass was then subjected to flash chromatography
on neutral Al2O3 using ethyl acetate as an eluent.
The resulted eluate was concentrated in vacuo to dryness. The formed
residue was chromatographed using silica gel column technique with
the EtOAc–hexane gradient elution. The obtained eluate was
finally concentrated in vacuo.

2,2-Dimethyl-4-phenyl-2H-imidazole 1-oxide 1a, 3-phenyl-1,4-diazaspiro[4.5]deca-1,3-diene
1-oxide 1c,22 and 2-ethyl-2-methyl-4-phenyl-2H-imidazole 1-oxide 1b(15b) were prepared according to the published procedures. Thiophene 2a, 2-acetylthiophene 2b, pyrrole 2c, 1-methylpyrrole 2d, 2-acetyl-1H-pyrrole 2e, 2-phenyl-1H-pyrrole 2f,
4,5,6,7-tetrahydro-1H-indole 2g, palladium(II)
acetate, copper(II) acetate monohydrate, pyridine, and 1,4-dioxane
were purchased from commercial sources.

Characterization Data for
All Products (3a–r)
5-(5-Acetylthiophen-2-yl)-2,2-dimethyl-4-phenyl-2H-imidazole 1-Oxide (3a)
Yield: 200
mg (64%),
mp = 137–142 °C. Rf 0.2 (heptane/EtOAc,
6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.61 (s, 6H); 2.53 (s, 3H); 6.96 (d, 1H, J = 4.16); 7.57–7.70 (m, 5H); 7.81 (d, 1H, J = 4.12) ppm. 13C NMR (DMSO-d6): δ 24.0 (CH3); 26.8 (CH3); 99.5 (C); 127.9 (CH); 128.2 (CH); 128.5 (CH); 130.5 (CH); 131.4
(C); 132.0 (CH); 133.0 (C); 133.9 (C); 142.2 (C); 164.5 (C); 191.3
(C) ppm. IR (DRA): ν 3850, 3243, 3188, 3167, 3141, 2978, 1602,
1579, 1519, 1442, 1133, 917, 735, 696, 580 cm–1.
MS (EI): m/z 312 [M]+. Anal. calcd for C17H16N2O2S: C, 65.36; H, 5.16; N, 8.97; O, 10.24; S, 10.26. Found:
C, 64.89; H, 4.81; N, 7.82.

2,2-Dimethyl-4-phenyl-5-(thiophen-2-yl)-2H-imidazole
1-Oxide (3b)
Yield: 151 mg (56%), mp = 107–112
°C. Rf 0.3 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.59 (s, 6H); 6.99 (d, 1H, J = 3.12);
7.08 (t, 1H, J = 4.08); 7.58–7.68 (m, 5H);
7.74 (d, 1H, J = 4.64) ppm. 13C NMR (DMSO-d6): δ 24.1 (CH3); 98.6 (C);
126.5 (CH); 127.4 (CH); 127.6 (C); 128.2 (CH); 128.3 (CH); 128.5 (CH);
130.5 (CH); 131.5 (C); 133.5 (C); 165.2 (C) ppm. IR (DRA): ν
1478, 1446, 1420, 1384, 1367, 1354, 1318, 1244, 1228, 1194, 1155,
765, 742, 727, 697, 646 cm–1. MS (EI): m/z 270 [M]+. Anal. calcd for C15H14N2OS: C, 66.64; H, 5.22; N, 10.36; O, 5.92;
S, 11.86. Found: C, 66.62; H, 5.13; N, 9.91.

2,2-Dimethyl-5-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-2H-imidazole 1-Oxide
(3c)
Yield: 208
mg (78%), mp = 97–102 °C. Rf 0.1 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.59 (s, 6H); 3.49 (s, 3H);
6.01–6.02 (m, 1H); 6.10–6.12 (m, 1H); 7.00–7.01
(m, 1H); 7.39–7.43 (m, 2H); 7.48–7.55 (m, 3H) ppm. 13C NMR (DMSO-d6): δ 24.4
(CH3); 34.7 (CH3); 99.0 (C); 108.1 (CH); 112.5
(CH); 118.4 (C); 125.3 (CH); 127.8 (CH); 128.2 (CH); 130.0 (C); 130.9
(CH); 131.9 (C); 165.1 (C) ppm. IR (DRA): ν 1544, 1502, 1444,
1429, 1386, 1345, 1329, 1245, 1227, 1182, 1155, 1094, 1059, 1028,
946, 775, 733, 695, 665, 654 cm–1. MS (EI): m/z 267 [M]+. Anal. calcd for
C16H17N3O: C, 71.89; H, 6.41; N,
15.72; O, 5.98. Found: C, 71.72; H, 6.60; N, 15.68.

2,2-Dimethyl-4-phenyl-5-(1H-pyrrol-2-yl)-2H-imidazole 1-Oxide (3d)
Yield: 170
mg (67%), mp = 99–104 °C. Rf 0.2 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.57 (s, 6H); 5.81–5.83
(m, 1H); 6.09–6.11 (m, 1H); 7.01–7.03 (m, 1H); 7.53–7.65
(m, 5H); 12.07 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 24.0 (CH3); 98.4 (C); 109.4 (CH);
111.6 (CH); 119.4 (C); 121.6 (CH); 128.76 (CH); 128.82 (CH); 129.7
(C); 130.9 (CH); 134.0 (C); 166.1 (C) ppm. IR (DRA): ν 1553,
1479, 1438, 1421, 1390, 1365, 1330, 1194, 1166, 1112, 1067, 1040,
967, 776, 731, 700, 663, 648, 595 cm–1. MS (EI): m/z 253 [M]+. Anal. calcd for
C15H15N3O: C, 71.13; H, 5.97; N,
16.59; O, 6.32. Found: C, 71.30; H, 6.00; N, 16.54.

2,2-Dimethyl-4-phenyl-5-(5-phenyl-1H-pyrrol-2-yl)-2H-imidazole 1-Oxide (3e)
Yield: 197
mg (60%), mp = 125–130 °C. Rf 0.2 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.62 (s, 6H); 5.98–6.00
(m, 1H); 6.68 (t, 1H, J = 3.36); 7.28 (t, 1H, J = 7.36); 7.42 (t, 2H, J = 7.72); 7.56–7.71
(m, 7H); 12.30 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 24.0 (CH3); 98.3 (C); 107.6 (CH);
112.9 (CH); 120.5 (C); 123.9 (CH); 127.1 (CH); 128.1 (CH); 128.2 (CH);
128.9 (CH); 129.0 (C); 130.5 (CH); 130.8 (C); 132.6 (C); 133.0 (C);
164.8 (C) ppm. IR (DRA): ν 3256, 3168, 3146, 3115, 2974, 2933,
1601, 1579, 1519, 1418, 1120, 1042, 931, 736, 696 cm–1. MS (EI): m/z 329 [M]+. Anal. calcd for C21H19N3O: C,
76.57; H, 5.81; N, 12.76; O, 4.86. Found: C, 76.64; H, 5.76; N, 12.80.

2,2-Dimethyl-4-phenyl-5-(4,5,6,7-tetrahydro-1H-indol-2-yl)-2H-imidazole 1-Oxide (3f)
Yield: 129
mg (42%), mp = 141–146 °C. Rf 0.2 (heptane/EtOAc, 6:4). 1H NMR
(DMSO-d6 + CCl4): δ 1.56
(d, 6H, J = 6.12); 1.59–1.61 (m, 2H); 1.68–1.70
(m, 2H); 2.30 (t, 2H, J = 5.82); 2.60 (t, 2H, J = 6.00); 5.58 (d, 1H, J = 2.04); 7.54–7.63
(m, 5H); 11.60 (s, 1H) ppm. 13C NMR (DMSO-d6): 22.2 (CH2); 22.51 (CH2); 22.54
(CH2); 23.0 (CH2); 24.0 (CH3); 97.4
(C); 110.0 (CH); 117.2 (C); 117.9 (C); 128.0 (CH); 128.1 (CH); 128.9
(C); 130.2 (CH); 130.4 (C); 133.5 (C); 165.3 (C) ppm. IR (DRA): ν
2932, 1522, 1489, 1443, 1407, 1320, 1303, 1260, 1237, 1170, 1144,
1092, 1073, 1003, 975, 922, 803, 772, 696, 655 cm–1. MS (EI): m/z 307 [M]+. Anal. calcd for C19H21N3O: C,
74.24; H, 6.89; N, 13.67; O, 5.20. Found: C, 74.10; H, 7.00; N, 13.76.

5-(5-Acetylthiophen-2-yl)-2-ethyl-2-methyl-4-phenyl-2H-imidazole 1-Oxide (3g)
Yield: 245
mg (75%), mp = 121–126 °C. Rf 0.1 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.59 (t, 3H, J = 7.32); 1.61 (s, 3H); 1.95–2.00 (m, 1H); 2.14–2.19
(m, 1H); 2.53 (s, 3H); 6.97 (d, 1H, J = 4.24); 7.58–7.70
(m, 5H); 7.82 (d, 1H, J = 4.28) ppm. 13C NMR (DMSO-d6): 6.7 (CH3);
23.0 (CH3); 26.9 (CH3); 30.3 (CH2); 102.0 (C); 128.0 (CH); 128.3 (CH); 128.7 (CH); 130.7 (CH); 132.2
(CH); 132.6 (C); 133.1 (C); 133.6 (C); 142.3 (C); 165.6 (C); 191.5
(C) ppm. IR (DRA): ν 1659, 1611, 1575, 1499, 1447, 1381, 1368,
1349, 1306, 1266, 1197, 1148, 944, 812 cm–1. MS
(EI): m/z 326 [M]+. Anal.
calcd for C18H18N2O2S:
C, 66.23; H, 5.56; N, 8.58; O, 9.80; S, 9.82. Found: C, 65.93; H,
5.36; N, 7.95.

2-Ethyl-2-methyl-4-phenyl-5-(thiophen-2-yl)-2H-imidazole 1-Oxide (3h)
Yield: 170
mg (60%),
mp = 83–88 °C. Rf 0.3 (heptane/EtOAc,
6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.58 (t, 3H, J = 7.28); 1.59 (s,
3H); 1.94–2.01 (m, 1H); 2.10–2.17 (m, 1H); 7.01 (d,
1H, J = 3.52); 7.09 (t, 1H, J =
4.48); 7.57–7.67 (m, 5H); 7.74 (d, 1H, J =
4.8 ppm). 13C NMR (DMSO-d6):
6.7 (CH3); 23.1 (CH3); 30.1 (CH2);
101.0 (C); 126.6 (CH); 127.2 (C); 127.4 (CH); 128.2 (CH); 128.3 (CH);
128.6 (CH); 130.5 (CH); 132.6 (C); 133.4 (C); 166.2 (C) ppm. IR (DRA):
ν 3330, 3274, 3213, 3180, 2968, 2855, 1641, 1603, 1537, 1443,
1372, 1180, 1143, 941, 694 cm–1. MS (EI): m/z 284 [M]+. Anal. calcd for
C16H16N2OS: C, 67.58; H, 5.67; N,
9.85; O, 5.63; S, 11.28. Found: C, 67.02; H, 5.43; N, 9.64.

2-Ethyl-2-methyl-5-(1-methyl-1H-pyrrol-2-yl)-4-phenyl-2H-imidazole 1-Oxide
(3i)
Yield: 197
mg (70%), mp = 79–84 °C. Rf 0.2 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.63 (t, 3H, J = 7.32); 1.58 (s, 3H); 1.92–1.98 (m, 1H); 2.12–2.17
(m, 1H); 3.49 (s, 3H); 5.98–5.99 (m, 1H); 6.10–6.12
(m, 1H); 7.02 (t, 1H, J = 2.12); 7.40–7.43
(m, 2H); 7.49–7.53 (m, 3H) ppm. 13C NMR (DMSO-d6): δ 6.8 (CH3); 23.8 (CH3); 30.2 (CH2); 35.0 (CH3); 101.5 (C);
108.2 (CH); 112.5 (CH); 118.4 (C); 125.5 (CH); 127.8 (CH); 128.3 (CH);
131.0 (CH); 131.3 (C); 131.9 (C); 166.2 (C) ppm. IR (DRA): ν
1545, 1505, 1487, 1461, 1447, 1433, 1379, 1350, 1331, 1281, 1179,
954, 721, 693, 660 cm–1. MS (EI): m/z 281 [M]+. Anal. calcd for C17H19N3O: C, 72.57; H, 6.81; N, 14.94; O, 5.69.
Found: C, 72.00; H, 6.86; N, 14.53.

2-Ethyl-2-methyl-4-phenyl-5-(1H-pyrrol-2-yl)-2H-imidazole 1-Oxide (3j)
Yield: 134
mg (50%), mp = 89–94 °C. Rf 0.2 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.60 (t, 3H, J = 7.24); 1.57 (s, 3H); 1.94–1.99 (m, 1H); 2.09–2.14
(m, 1H); 5.82 (s, 1H); 6.10 (d, 1H, J = 2.64); 7.02
(s, 1H); 7.54–7.64 (m, 5H); 12.08 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 6.8 (CH3); 23.2 (CH3); 29.9 (CH2); 100.4 (C);
109.0 (CH); 111.2 (CH); 118.6 (C); 121.1 (CH); 128.2 (CH); 128.4 (CH);
130.3 (C); 130.4 (CH); 133.4 (C); 166.4 (C) ppm. IR (DRA): ν
3293, 1557, 1446, 1409, 1391, 1362, 1325, 1196, 1114, 1070, 1043,
824, 760, 734, 701, 659, 599 cm–1. MS (EI): m/z 267 [M]+. Anal. calcd for
C16H17N3O: C, 71.89; H, 6.41; N,
15.72; O, 5.98. Found: C, 71.12; H, 6.66; N, 14.67.

2-Ethyl-2-methyl-4-phenyl-5-(5-phenyl-1H-pyrrol-2-yl)-2H-imidazole 1-Oxide (3k)
Yield: 199
mg (58%), mp = 75–80 °C. Rf 0.3 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.64 (t, 3H, J = 7.30); 1.61 (s, 3H); 1.98–2.03 (m, 1H); 2.14–2.19
(m, 1H); 5.99–6.00 (m, 1H); 6.68 (t, 1H, J = 3.36); 7.29 (t, 1H, J = 7.36); 7.42 (t, 2H, J = 7.72); 7.58–7.70 (m, 7H); 12.28 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 6.8
(CH3); 23.2 (CH3); 30.0 (CH2); 100.8
(C); 107.8 (CH); 113.1 (CH); 120.2 (C); 124.0 (CH); 127.2 (CH); 128.2
(CH); 128.5 (CH); 129.1 (CH); 130.2 (C); 130.7 (CH); 130.9 (C); 132.8
(C); 133.0 (C); 165.9 (C) ppm. IR (DRA): ν 3449, 2927, 2847,
1601, 1572, 1535, 1487, 1443, 1269, 955, 752, 690, 646, 565 cm–1. MS (EI): m/z 343
[M]+. Anal. calcd for C22H21N3O: C, 76.94; H, 6.16; N, 12.24; O, 4.66. Found: C, 74.66;
H, 6.15; N, 11.74.

5-(5-Acetyl-1H-pyrrol-2-yl)-2-ethyl-2-methyl-4-phenyl-2H-imidazole 1-Oxide (3l)
Yield: 167
mg (54%), mp = 157–162 °C. Rf 0.1 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 0.58 (t, 3H, J = 7.28); 1.55 (s, 3H); 1.91–1.96 (m, 1H); 2.08–2.13
(m, 1H); 2.25 (s, 3H); 7.05 (s, 1H); 7.56–7.64 (m, 6H); 12.27
(s, 1H) ppm. 13C NMR (DMSO-d6): δ 6.7 (CH3); 23.3 (CH3); 25.5 (CH3); 30.1 (CH2); 100.8 (C); 110.8 (C); 114.5 (CH);
125.7 (CH); 128.2 (CH); 128.5 (CH); 130.5 (CH); 131.5 (C); 131.9 (C);
133.5 (C); 167.2 (C); 187.2 (C) ppm. IR (DRA): ν 3131, 2970,
1658, 1569, 1445, 1360, 1339, 1306, 1186, 1135, 1083, 952, 940, 838,
766, 701, 629 cm–1. MS (EI): m/z 309 [M]+. Anal. calcd for C18H19N3O2: C, 69.88; H, 6.19; N, 13.58;
O, 10.34. Found: C, 69.63; H, 6.27; N, 13.36.

2-(5-Acetylthiophen-2-yl)-3-phenyl-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3m)
Yield: 246 mg (70%), mp = 163–168 °C. Rf 0.3 (heptane/EtOAc, 6:4). 1H NMR
(DMSO-d6 + CCl4): δ 1.40–1.43
(m, 1H); 1.56 (d, 2H, J = 12.36); 1.72–1.89
(m, 5H); 2.03–2.10 (m, 2H); 2.52 (s, 3H); 6.96 (d, 1H, J = 4.24); 7.58–7.70 (m, 5H); 7.81 (d, 1H, J = 4.28) ppm. 13C NMR (DMSO-d6): δ 22.7 (CH2); 24.2 (CH2); 26.8 (CH3); 34.4 (CH2); 101.8 (C); 127.8
(CH); 128.3 (CH); 128.5 (CH); 130.4 (CH); 131.6 (C); 132.0 (CH); 133.3
(C); 133.9 (C); 142.1 (C); 164.7 (C); 191.3 (C) ppm. IR (DRA): ν
2933, 2921, 2860, 1650, 1560, 1446, 1383, 1363, 1309, 1273, 1196,
959, 818, 773, 707, 695, 657 cm–1. MS (EI): m/z 352 [M]+. Anal. calcd for
C20H20N2O2S: C, 68.16;
H, 5.72; N, 7.95; O, 9.08; S, 9.10. Found: C, 68.15; H, 5.66; N, 7.56.

3-Phenyl-2-(thiophen-2-yl)-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3n)
Yield: 202 mg (65%), mp = 179–184 °C. Rf 0.4 (heptane/EtOAc, 6:4). 1H NMR
(DMSO-d6 + CCl4): δ 1.44–1.52
(m, 3H); 1.80–1.88 (m, 5H); 7.04 (d, 2H, J = 3.24); 7.56–7.67 (m, 6H) ppm. 13C NMR (DMSO-d6): δ 22.5 (CH2); 24.1 (CH2); 34.4 (CH2); 100.7 (C); 126.1 (CH); 127.1 (CH);
127.3 (C); 127.8 (CH); 128.0 (CH); 128.2 (CH); 130.0 (CH); 131.3 (C);
133.5 (C); 165.1 (C) ppm. IR (DRA): ν 3063, 2933, 2860, 1566,
1496, 1477, 1444, 1422, 1383, 1359, 1339, 1324, 1292, 959, 770, 735,
702, 659, 629 cm–1. MS (EI): m/z 310 [M]+. Anal. calcd for C18H18N2OS: C, 69.65; H, 5.84; N, 9.02; O, 5.15; S,
10.33. Found: C, 68.87; H, 5.69; N, 8.71.

2-(1-Methyl-1H-pyrrol-2-yl)-3-phenyl-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3o)
Yield: 184 mg (60%), mp = 157–162
°C. Rf 0.3 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.40–1.52 (m, 3H); 1.83–1.88 (m, 5H); 2.02–2.09
(m, 2H); 3.46 (s, 3H); 6.00–6.02 (m, 1H); 6.10–6.11
(m, 1H); 7.00 (t, 1H, J = 2.06); 7.41 (t, 2H, J = 7.44); 7.49–7.54 (m, 3H) ppm. 13C
NMR (DMSO-d6): δ 22.6 (CH2); 24.3 (CH2); 34.5 (CH3); 34.8 (CH2); 101.2 (C); 107.9 (CH); 112.2 (CH); 118.3 (C); 125.0 (CH); 127.6
(CH); 128.0 (CH); 130.0 (C); 130.6 (CH); 132.1 (C); 165.3 (C) ppm.
IR (DRA): ν 2941, 2927, 1544, 1503, 1487, 1443, 1377, 1350,
1329, 1278, 1167, 961, 728, 688, 675, 658, 609 cm–1. MS (EI): m/z 307 [M]+. Anal. calcd for C19H21N3O: C,
74.24; H, 6.89; N, 13.67; O, 5.20. Found: C, 74.26; H, 7.00; N, 13.60.

3-Phenyl-2-(1H-pyrrol-2-yl)-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3p)
Yield: 135 mg (46%), mp = 195–200
°C. Rf 0.4 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.38–1.49 (m, 3H); 1.75–1.88 (m, 5H); 2.10
(t, 2H, J = 11.64); 5.81 (s, 1H); 6.09 (d, 1H, J = 2.76); 7.01 (s, 1H); 7.53–7.64 (m, 5H); 12.07
(s, 1H) ppm. 13C NMR (DMSO-d6): δ 22.9 (CH2); 24.4 (CH2); 34.4 (CH2); 100.2 (C); 108.9 (CH); 111.1 (CH); 118.9 (C); 121.0 (CH);
128.26 (CH); 128.28 (CH); 129.3 (C); 130.3 (CH); 133.7 (C); 165.6
(C) ppm. IR (DRA): ν 3284, 2943, 2922, 2851, 1498, 1441, 1408,
1392, 1373, 1332, 1113, 1088, 1058, 996, 729, 696 cm–1. MS (EI): m/z 293 [M]+. Anal. calcd for C18H19N3O: C,
73.69; H, 6.53; N, 14.32; O, 5.45. Found: C, 73.54; H, 6.55; N, 14.27.

3-Phenyl-2-(4,5,6,7-tetrahydro-1H-indol-2-yl)-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3q)
Yield: 132 mg (40%), mp = 167–172
°C. Rf 0.4 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.43 (d, 2H, J = 12.64); 1.59–1.84
(m, 10H); 2.06–2.12 (m, 2H); 2.29 (d, 2H, J = 5.56); 2.58 (d, 2H, J = 5.8); 5.55 (d, 1H, J = 1.16); 7.53–7.62 (m, 5H); 11.62 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 22.1
(CH2); 22.5 (CH2); 22.6 (CH2); 23.0
(CH2); 24.3 (CH2); 34.3 (CH2); 99.5
(C); 109.8 (CH); 117.2 (C); 117.8 (C); 128.0 (CH); 129.0 (C); 130.0
(CH); 130.2 (C); 133.7 (C); 165.5 (C) ppm. IR (DRA): ν 2924,
2851, 1601, 1538, 1489, 1442, 1336, 1267, 1233, 1184, 1009, 971, 954,
698, 566 cm–1. MS (EI): m/z 347 [M]+. Anal. calcd for C22H25N3O: C, 76.05; H, 7.25; N, 12.09; O, 4.60. Found:
C, 76.14; H, 7.30; N, 12.11.

2-(5-Acetyl-1H-pyrrol-2-yl)-3-phenyl-1,4-diazaspiro[4.5]deca-1,3-diene
1-Oxide (3r)
Yield: 147 mg (44%), mp = 195–200
°C. Rf 0.1 (heptane/EtOAc, 6:4). 1H NMR (DMSO-d6 + CCl4): δ 1.42 (d, 2H, J = 12.16); 1.79 (t, 6H, J = 14.58); 2.06 (t, 2H, J = 11.16); 2.24
(s, 3H); 7.04 (s, 1H); 7.56–7.64 (m, 6H); 12.24 (s, 1H) ppm. 13C NMR (DMSO-d6): δ 22.9
(CH2); 24.5 (CH2); 25.5 (CH3); 34.6
(CH2); 100.7 (C); 111.1 (C); 114.6 (CH); 125.8 (CH); 128.3
(CH); 128.4 (CH); 130.4 (CH); 130.9 (C); 131.4 (C); 133.8 (C); 166.4
(C); 187.2 (C) ppm. IR (DRA): ν 3236, 2938, 1647, 1561, 1442,
1367, 1331, 1300, 1236, 1065, 1002, 831, 786, 773, 710 cm–1. MS (EI): m/z 335 [M]+. Anal. calcd for C20H21N3O2: C, 71.62; H, 6.31; N, 12.53; O, 9.54. Found: C, 70.00; H,
6.53; N, 11.59.

General Procedure for the H/D Exchange Control
Experiments
The hydrogen–deuterium exchange control
experiments were
carried out according to the literature procedure.19 The deuteration reactions of either 2H-imidazole 1-oxide 1a or 2-acetylthiophene 2b separately carried out using the conditions noted in Table 3. Heavy water D2O
(20.0 mmol) was used as a deuterium source. All reaction mixtures
were refluxed at 110–120 °C for 24 h in 1,4-dioxane (5
mL). Then, the mixture was cooled to room temperature, filtered through
neutral alumina, and concentrated in vacuo. The obtained residues
were individually analyzed by means of 1H NMR spectroscopy.

Supporting Information Available
The
Supporting Information
is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.8b02916.1H
and 13C NMR spectra of 3a–r; 1H–13C heteronuclear
single quantum coherence, 1H–13C heteronuclear
multiple bond correlation, and 1H–1H
nuclear Overhauser effect spectroscopy 2D NMR spectra of 3c; 1H NMR spectra of reaction mixtures, isolated during
the H/D exchange control experiments (PDF)



Supplementary Material
ao8b02916_si_001.pdf

 The authors declare no
competing financial interest.

Acknowledgments
The research was financially
supported by the Russian Science
Foundation (Project no. 18-73-00088).
==== Refs
References
a Heterocyclic
N-Oxides ; Larionov O. V.  , Ed.; Springer : Heidelberg , 2017 .b Cerecetto H. ; Dias E. ; Di Maio R. ; Gonzalez M. ; Pacce S. ; Saenz P. ; Seoane G. ; et al. Synthesis and Herbicidal
Activity of N-Oxide Derivatives . J. Agric. Food Chem. 
2000 , 48 , 2995 –3002 . 10.1021/jf9904766 .10898655  c Messenger A.
G. ; Rundegren J. 
Minoxidil:
mechanisms of action on hair growth . Br. J.
Dermatol. 
2004 , 150 , 186 –194 . 10.1111/j.1365-2133.2004.05785.x .14996087  d Padois K. ; Cantien C. ; Bertholle V. ; et al. Solid lipid nanoparticles suspension versus commercial solutions
for dermal delivery of minoxidil . Int. J. Pharm. 
2011 , 416 , 300 –304 . 10.1016/j.ijpharm.2011.06.014 .21704140 
a Mfuh A. M. ; Larionov O. V. 
Heterocyclic N-Oxides
- An Emerging Class of Therapeutic Agents . Curr.
Med. Chem. 
2015 , 22 , 2819 –2857 . 10.2174/0929867322666150619104007 .26087764  b Oliveira C. ; Benfeito S. ; Fernandes C. ; Cagide F. ; Silva T. ; Borges F. 
NO and HNO donors,
nitrones, and nitroxides: Past, present, and future . Med. Res. Rev. 
2018 , 38 , 1159 –1187 . 10.1002/med.21461 .29095519  c Anderson L.
L. 
Diverse Applications
of Nitrones for the Synthesis of Heterocyclic Compounds . Asian J. Org. Chem. 
2016 , 5 , 9 –30 . 10.1002/ajoc.201500211 . d Zhang G. ; Zhang T. ; Li N. ; Wu L. ; Gu J. ; Li C. ; Zhao C. ; Liu W. ; Shan L. ; Yu P. ; Yang X. ; Tang Y. ; Yang G.-Y. ; Wang Y. ; Sun Y. ; Zhang Z. 
Tetramethylpyrazine nitrone activates the BDNF/Akt/CREB
pathway to promote post-ischaemic neuroregeneration and recovery of
neurological functions in rats . Br. J. Pharmacol. 
2018 , 175 , 517 –531 . 10.1111/bph.14102 .29161771 
a Ihsan A. ; Wang X. ; Tu H.-G. ; Zhang W. ; Dai M.-H. ; Peng D.-P. ; Wang Y.-L. ; Huang L.-L. ; Chen D.-M. ; Mannan S. ; Tao Y.-F. ; Liu Z.-L. ; Yuan Z.-H. 
Genotoxicity evaluation of Mequindox in different short-term
tests . Food Chem. Toxicol. 
2013 , 51 , 330 –336 . 10.1016/j.fct.2012.10.003 .23063596  b Palani A. ; Tagat J. R. 
Discovery and Development of Small-Molecule Chemokine
Coreceptor CCR5 Antagonists . J. Med. Chem. 
2006 , 49 , 2851 –2857 . 10.1021/jm060009x .16686527  c Debnath A. K. 
Generation
of Predictive Pharmacophore Models for CCR5 Antagonists: Study with
Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1
Entry Inhibitors . J. Med. Chem. 
2003 , 46 , 4501 –4515 . 10.1021/jm030265z .14521412  d Tagat J. R. ; Steensma R. W. ; McCombie S. W. ; Dennis V. ; Nazaren D. V. ; Lin S. L. ; Neustadt B. R. ; Cox K. ; Xu S. ; Wojcik L. ; Murray M. G. ; Vantuno N. ; Baroudy B. M. ; Strizki J. M. 
Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors.
II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5
Antagonist . J. Med. Chem. 
2001 , 44 , 3343 –3346 . 10.1021/jm0155401 .11585438  e Ganley B. ; Chowdhury G. ; Bhansali J. ; Daniels J. S. ; Gates K. S. 
Redox-activated,
hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide . Bioorg. Med. Chem. 
2001 , 9 , 2395 –2401 . 10.1016/S0968-0896(01)00163-8 .11553481  f Miroshnikova O. V. ; Hudson T. H. ; Gerena L. ; Kyle D. E. ; Lin A. J. 
Synthesis
and Antimalarial Activity of New Isotebuquine Analogues . J. Med. Chem. 
2007 , 50 , 889 –896 . 10.1021/jm061232x .17266295  g Ibrahim H. ; Furiga A. ; Najahi E. ; Pigasse
Hénocq C. ; Nallet J. P. ; Roques C. ; Aubouy A. ; Sauvain M. ; Constant P. ; Daffé M. ; Nepveu F. 
Antibacterial, antifungal and antileishmanial activities
of indolone-N-oxide derivatives . J. Antibiot. 
2012 , 65 , 499 –504 . 10.1038/ja.2012.60 .22828966  h Benítez D. ; Casanova G. ; Cabrera G. ; Galanti N. ; Cerecetto H. ; González M. 
Initial studies
on mechanism of action and cell death of active N-oxide-containing heterocycles in Trypanosoma cruzi epimastigotes in vitro . Parasitology 
2014 , 141 , 682 –696 . 10.1017/S003118201300200X .24476762  i Robert A. F. ; Chandru H. K. ; He T. ; Towner R. 
Anti-Cancer
Activity of Nitrones and Observations on Mechanism of Action . Anti-Cancer Agents Med. Chem. 
2011 , 11 , 373 –379 . 10.2174/187152011795677517 . j Barriga G. ; Olea-Azar C. ; Norambuena E. ; Castro A. ; Porcal W. ; Gerpe A. ; González M. ; Cerecetto H. 
New heteroaryl
nitrones with spin trap properties: Identification of a 4-furoxanyl
derivative with excellent properties to be used in biological systems . Bioorg. Med. Chem. 
2010 , 18 , 795 –802 . 10.1016/j.bmc.2009.11.053 .20031416  k Rosselin M. ; Poeggeler B. ; Durand G. 
Nitrone Derivatives
as Therapeutics: From Chemical Modification to Specific-targeting . Curr. Top. Med. Chem. 
2017 , 17 , 2006 –2022 . 10.2174/1568026617666170303115324 .28260508  l Floyd R. A. ; Kopke R. D. ; Choi C. H. ; Foster S. B. ; Doblas S. ; Towner R. A. 
Nitrones as Therapeutics . Free
Radical Biol. Med. 
2008 , 45 , 1361 –1374 . 10.1016/j.freeradbiomed.2008.08.017 .18793715  m Porcal W. ; Hernández P. ; González M. ; Ferreira A. ; Olea-Azar C. ; Cerecetto H. ; Castro A. 
Heteroarylnitrones as Drugs for Neurodegenerative Diseases:
Synthesis, Neuroprotective Properties, and Free Radical Scavenger
Properties . J. Med. Chem. 
2008 , 51 , 6150 –6159 . 10.1021/jm8006432 .18788732 
a Chlordiazepoxide, DrugBank ID DB00475 (APRD00682). https://www.drugbank.ca/drugs/DB00475, (accessed April 2018 );b Skerritt J. H. ; Johnston G. A. 
Enhancement
of GABA binding by benzodiazepines and related anxiolytics . Eur. J. Pharmacol. 
1983 , 89 , 193 –198 . 10.1016/0014-2999(83)90494-6 .6135616  c McKernan R. M. ; Rosahl T. W. ; Reynolds D. S. ; Sur C. ; Wafford K. A. ; Atack J. R. ; Farrar S. ; Myers J. ; Cook G. ; Ferris P. ; Garrett L. ; Bristow L. ; Marshall G. ; Macaulay A. ; Brown N. ; Howell O. ; Moore K. W. ; Carling R. W. ; Street L. J. ; Castro J. L. ; Ragan C. I. ; Dawson G. R. ; Whiting P. J. 
Sedative but not
anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype . Nat. Neurosci. 
2000 , 3 , 587 –592 . 10.1038/75761 .10816315 
Lumeras W. ; Vidal L. ; Vidal B. ; Balague C. ; Orellana A. ; Maldonado M. ; Domińguez M. ; Segarra V. ; Caturla F. 
1,7-Naphthyridine
1-oxides as novel potent and selective inhibitors of p38 mitogen activated
protein kinase . J. Med. Chem. 
2011 , 54 , 7899 –7910 . 10.1021/jm200975u .21999461 
a Schiefer I. T. ; VandeVrede L. ; Fá M. ; Arancio O. ; Thatcher G. R. J. 
Furoxans (1,2,5-Oxadiazole-N-Oxides) as Novel NO Mimetic Neuroprotective and Procognitive
Agents . J. Med. Chem. 
2012 , 55 , 3076 –3087 . 10.1021/jm201504s .22429006  b Aguirre G. ; Boiani M. ; Cerecetto H. ; Fernández M. ; González M. ; León E. ; Pintos C. ; Raymondo S. ; Arredondo C. ; Pacheco J. P. ; Basombrío M. 
Furoxan derivatives
as cytotoxic agents: preliminary in vivo antitumoral activity studies . Pharmazie 
2006 , 61 , 54 –59 .16454207 
a Goldstein S. ; Lestage P. 
Chemical and pharmacological aspects
of heteroaryl-nitrones . Curr. Med. Chem. 
2000 , 7 , 1255 –1267 . 10.2174/0929867003374183 .11032970 b Sumitomo Pharma ; Ikeda K. ; Tatsuno T. ; Ogo H. ; Masumoto S. ; Fugibayashi T. ; Najata R.  Nitrone
Derivatives . WO9813332 , 1998 . c Nepveu F. ; Souchard J. P. ; Rolland Y. ; Dorey G. ; Spedding M. 
2-2′-Pyridylisatogen,
a selective allosteric modulator of P2 receptors, is a spin trapping
agent . Biochem. Biophys. Res. Commun. 
1998 , 242 , 272 –276 . 10.1006/bbrc.1997.7949 .9446783 
a Zhao D. ; You J. ; Hu C. 
Recent Progress
in
Coupling of Two Heteroarenes . Chem. - Eur. J. 
2011 , 17 , 5466 –5492 . 10.1002/chem.201003039 .21506178  b Yang Y. ; Lan J. ; You J. 
Oxidative C–H/C–H Coupling Reactions
between Two (Hetero)arenes . Chem. Rev. 
2017 , 117 , 8787 –8863 . 10.1021/acs.chemrev.6b00567 .28085272 c Simonetti M. ; Cannas D. M. ; Larrosa I.  Biaryl
Synthesis via C–H Bond Activation: Strategies and Methods . In Advances in Organometallic Chemistry ; 1 st ed., Pérez P. J.  , Ed.; Elsevier : Amsterdam , 2017 ; Chapter 4; Vol. 67 , pp 299 –399 . d Perry G. J. P. ; Larrosa I. 
Recent Progress in Decarboxylative Oxidative Cross-Coupling
for Biaryl Synthesis . Eur. J. Org. Chem. 
2017 , 2017 , 3517 –3527 . 10.1002/ejoc.201700121 .e Yamaguchi J. ; Itami K.  Biaryl Synthesis through Metal-Catalyzed
C–H Arylation . In Metal Catalyzed Cross-Coupling
Reactions and More , 1 st ed.; de Meijere A. ; Bräse S. ; Oestreich M.  , Eds.; Wiley-VCH : Weinheim , 2014 ; Chapter
17, pp 1315 –1387 . f Mehta V. P. ; Punji B. 
Recent advances in transition-metal-free direct C–C and C–heteroatom
bond forming reactions . RSC Adv. 
2013 , 3 , 11957 –11986 . 10.1039/c3ra40813b .
a García-Melchor M. ; Solans-Monfort X. ; Ujaque G.  C–C
Bond Formation . In Comprehensive Inorganic
Chemistry II , 2 nd ed.; Reedijk J. ; Poeppelmeier K.  , Eds.; Elsevier : Amsterdam , 2013 ; Chapter
28; Vol. 9 , pp 767 –805 ;b Zhang Y. H. ; Shi G. F. ; Yu J.-Q.  Carbon–Carbon
σ-Bond Formation via CH Bond Functionalization . In Comprehensive Organic Synthesis II , 2 nd ed.; Knochel P. ; Molander G. A.  , Eds.; Elsevier : Oxford , 2014 ; Chapter 23; Vol. 3 , pp 1101 –1209 ;c Hoffman R. V.  Organic Chemistry:
An Intermediate Text , 2 nd ed.; John Wiley & Sons, Inc. : Hoboken , 2004 ;d Li C.-J.  , Ed. From C–H to C–C Bonds: Cross-Dehydrogenative
Coupling ; Royal Society of Chemistry : Cambridge , 2015 ;e Yeung C. S. ; Dong V. M. 
Catalytic Dehydrogenative Cross-Coupling: Forming Carbon–Carbon
Bonds by Oxidizing Two Carbon–Hydrogen Bonds . Chem. Rev. 
2011 , 111 , 1215 –1292 . 10.1021/cr100280d .21391561  f Abakumov G. A. ; Piskunov A. V. ; Cherkasov V. K. ; Fedushkin I. L. ; Ananikov V. P. ; Eremin D. B. ; Gordeev E. G. ; Beletskaya I. P. ; Averin A. D. ; Bochkarev M. N. ; Trifonov A. A. ; Dzhemilev U. M. ; Dyakonov V. A. ; Egorov M. P. ; Vereshchagin A. N. ; Syroeshkin M. A. ; Jouikov V. V. ; Muzafarov A. M. ; Anisimov A. A. ; Arzumanyan A. V. ; Kononevich Y. N. ; Temnikov M. N. ; Sinyashin O. G. ; Budnikova Y. H. ; Burilov A. R. ; Karasik A. A. ; Mironov V. F. ; Storozhenko P. A. ; Shcherbakova G. I. ; Trofimov B. A. ; Amosova S. V. ; Gusarova N. K. ; Potapov V. A. ; Shur V. B. ; Burlakov V. V. ; Bogdanov V. S. ; Andreev M. V. 
Organoelement chemistry: promising growth areas and
challenges . Russ. Chem. Rev. 
2018 , 87 , 393 –507 . 10.1070/RCR4795 .
a Sheldon R. A. 
Atom efficiency and catalysis in
organic synthesis . Pure Appl. Chem. 
2000 , 72 , 1233 –1246 . 10.1351/pac200072071233 .b Dicks A. P. ; Hent A.  Atom Economy and
Reaction Mass Efficiency . In Green Chemistry
Metrics: A Guide to Determining and Evaluating Process Greenness (SpringerBriefs
in Molecular Science) , 1 st ed.; Springer : Cham , 2015 ; Chapter 2, pp 17 –44 ; c Sheldon R. A. 
Fundamentals of green chemistry: efficiency in reaction
design . Chem. Soc. Rev. 
2012 , 41 , 1437 –1451 . 10.1039/C1CS15219J .22033698 d Sheldon R. A. ; Arends I. ; Hanefeld U.  Green Chemistry and Catalysis ; John Wiley & Sons : Weinheim , 2007 ; e Mulvihill M. J. ; Beach E. S. ; Zimmerman J. B. ; Anastas P. T. 
Green Chemistry
and Green Engineering: A Framework for Sustainable Technology Development . Annu. Rev. Environ. Resour. 
2011 , 36 , 271 –293 . 10.1146/annurev-environ-032009-095500 .f Lancaster M.  Green Chemistry.
An Introductory Text ; 2 nd ed.; RSC Publishing : Cambridge , 2010 ; p 328 . g Anastas P. ; Eghbali N. 
Green chemistry: principles and practice . Chem. Soc. Rev. 
2010 , 39 , 301 –312 . 10.1039/B918763B .20023854 
a Dixneuf P. H. ; Doucet H.  ,
Eds. C–H Bond Activation and Catalytic Functionalization
I and II ; Springer : Berlin , 2016 ;b Li J. J.  , Ed. C–H Bond
Activation in Organic Synthesis ; CRC Press : New York , 2015 ;c Murakami K. ; Yamada S. ; Kaneda T. ; Itami K. 
C–H
Functionalization of Azines . Chem. Rev. 
2017 , 117 , 9302 –9332 . 10.1021/acs.chemrev.7b00021 .28445033  d Shang R. ; Ilies L. ; Nakamura E. 
Iron-Catalyzed C–H
Bond Activation . Chem. Rev. 
2017 , 117 , 9086 –9139 . 10.1021/acs.chemrev.6b00772 .28378590  e Bohra H. ; Wang M. 
Direct C–H arylation: a “Greener”
approach towards facile synthesis of organic semiconducting molecules
and polymers . J. Mater. Chem. A 
2017 , 5 , 11550 –11571 . 10.1039/C7TA00617A . f Davies H. M. L. ; Morton D. 
Recent Advances in C–H Functionalization . J. Org. Chem. 
2016 , 81 , 343 –350 . 10.1021/acs.joc.5b02818 .26769355  g Zhu R. Y. ; Farmer M. E. ; Chen Y. Q. ; Yu J. Q. 
A Simple
and Versatile Amide Directing Group for C–H Functionalizations . Angew. Chem., Int. Ed. 
2016 , 55 , 10578 –10599 . 10.1002/anie.201600791 . h Zhu R.-Y. ; et al. Eine einfache und vielseitige dirigierende Amidgruppe
zur Funktionalisierung von C-H-Bindungen . Angew.
Chem. 
2016 , 128 , 10734 –10756 . 10.1002/ange.201600791 . i He F. ; Wang Z.-X. 
Nickel-catalyzed cross-coupling of
aryl or 2-menaphthyl quaternary ammonium triflates with organoaluminum
reagents . Tetrahedron 
2017 , 73 , 4450 –4457 . 10.1016/j.tet.2017.06.004 .j Charushin V. ; Chupakhin O.  , Eds. Metal Free C–H
Functionalization of Aromatics. Nucleophilic Displacement of Hydrogen ; Springer : Cham , 2014 .
a Liu C. ; Yuan J. ; Gao M. ; Tang S. ; Li W. ; Shi R. ; Lei A. 
Oxidative
Coupling between Two Hydrocarbons: An Update of Recent C–H
Functionalizations . Chem. Rev. 
2015 , 115 , 12138 –12204 . 10.1021/cr500431s .26558751  b Han W. ; Ofial A. R. 
No Detours: Palladium-Catalyzed Oxidative C–H/C–H
Cross-Couplings of Heteroarenes . Synlett 
2011 , 2011 , 1951 –1955 . 10.1055/s-0030-1260941 . c Liu C. ; Zhang H. ; Shi W. ; Lei A. 
Bond Formations between
Two Nucleophiles: Transition Metal Catalyzed Oxidative Cross-Coupling
Reactions . Chem. Rev. 
2011 , 111 , 1780 –1824 . 10.1021/cr100379j .21344855  d Sun C.-L. ; Shi Z.-J. 
Transition-Metal-Free Coupling Reactions . Chem. Rev. 
2014 , 114 , 9219 –9280 . 10.1021/cr400274j .25184859  e Cho S. H. ; Kim J. Y. ; Kwak J. ; Chang S. 
Recent advances
in the transition metal-catalyzed twofold oxidative C–H bond
activation strategy for C–C and C–N bond formation . Chem. Soc. Rev. 
2011 , 40 , 5068 –5083 . 10.1039/c1cs15082k .21643614  f Choy P. Y. ; Wong S. M. ; Kapdi A. ; Kwong F. Y. 
Recent developments in palladium-catalysed non-directed
coupling of (hetero)arene C–H bonds with C–Z (Z = B,
Si, Sn, S, N, C, H) bonds in bi(hetero)aryl synthesis . Org. Chem. Front. 
2018 , 5 , 288 –321 . 10.1039/C7QO00693D .
a Zubenko D. ; Kirilyuk I. ; Roschchupkina G. ; Zhurko I. ; Reznikov V. ; Marque S. R. A. ; Bagryanskaya E. 
2,5-Dihydro-1H-imidazole-Based Nitroxides as Prospective Mediators in
Living Radical Polymerization . Helv. Chim. Acta 
2006 , 89 , 2341 –2353 . 10.1002/hlca.200690218 . b Edeleva M. V. ; Parkhomenko D. A. ; Morozov D. A. ; Dobrynin S. A. ; Trofimov D. G. ; Kanagatov B. ; Kirilyuk I. A. ; Bagryanskaya E. G. 
Controlled/living
polymerization of methyl methacrylate using new sterically hindered
imidazoline nitroxides prepared via intramolecular 1,3-dipolar cycloaddition
reaction . J. Polym. Sci., Part A: Polym. Chem. 
2014 , 52 , 929 –943 . 10.1002/pola.27071 . c Varaksin M. V. ; Moseev T. D. ; Charushin V. N. ; Chupakhin O. N. 
Direct C–Li/C–H coupling of pentafluorophenyl
lithium with azines - An atom- and step-economical strategy for the
synthesis of polyfluoroaryl azaaromatics . J.
Organomet. Chem. 
2018 , 867 , 278 –283 . 10.1016/j.jorganchem.2018.01.020 .
a Voinov M. A. ; Shevelev T. G. ; Rybalova T. V. ; Gatilov Y. V. ; Pervukhina N. V. ; Burdukov A. B. ; Grigor’ev I. A. 
α-Organoelement
Nitrones: Synthesis, Properties, and IR and 13C NMR Spectral
and X-ray Structural Characterization . Organometallics 
2007 , 26 , 1607 –1615 . 10.1021/om060883o . b Varaksin M. V. ; Utepova I. A. ; Chupakhin O. N. ; Charushin V. N. 
Direct nuclophilic C–H functionalization of
azines and their N-oxides by lithium derivatives
of aldonitrones . Tetrahedron 
2015 , 71 , 7077 –7082 . 10.1016/j.tet.2015.04.061 . c Varaksin M. V. ; Utepova I. A. ; Chupakhin O. N. 
Direct
C–C coupling of cyclic aldonitrones with 1,2,4-triazines using
SNH reactions . Chem. Heterocycl.
Compd. 
2012 , 48 , 1213 –1219 . 10.1007/s10593-012-1124-x .
a Varaksin M. ; Moseev T. ; Chupakhin O. ; Charushin V. ; Trofimov B. 
Metal-free C–H functionalization
of 2H-imidazole 1-oxides with pyrrolyl fragments
in the design of novel azaheterocyclic ensembles . Org. Biomol. Chem. 
2017 , 15 , 8280 –8284 . 10.1039/C7OB01999H .28944818  b Varaksin M. V. ; Utepova I. A. ; Chupakhin O. N. ; Charushin V. N. 
Palladium(II)-Catalyzed Oxidative C–H/C–H
Coupling and Eliminative SNH Reactions in Direct
Functionalization of Imidazole Oxides with Indoles . J. Org. Chem. 
2012 , 77 , 9087 –9093 . 10.1021/jo301618b .22998018 
Xi P. ; Yang F. ; Qin S. ; Zhao D. ; Lan J. ; Gao G. ; Hu C. ; You J. 
Palladium(II)-Catalyzed Oxidative
C–H/C–H Cross-Coupling of Heteroarenes . J. Am. Chem. Soc. 
2010 , 132 , 1822 –1824 . 10.1021/ja909807f .20102197 
a Wu Y. ; Wang J. ; Mao F. ; Kwong F. Y. 
Palladium-Catalyzed
Cross-Dehydrogenative Functionalization
of C(sp2)–H Bonds . Chem. -
Asian J. 
2014 , 9 , 26 –47 . 10.1002/asia.201300990 .24123795  b Guo X. W. ; Li Z. ; Li C.-J. 
Cross-dehydrogenative-coupling
(CDC) reaction . Prog. Chem. 
2010 , 22 , 1434 –1441 . c Liu S. ; Tzschucke C. C. 
Palladium-Catalyzed Regioselective Dehydrogenative
C–H/C–H Cross-Coupling of Pyrroles and Pyridine N-Oxides . Eur. J. Org. Chem. 
2016 , 2016 , 3509 –3513 . 10.1002/ejoc.201600680 . d Varun B. V. ; Dhineshkumar J. ; Bettadapur K. R. ; Siddaraju Y. ; Alagiri K. ; Ramaiah Prabhu K. 
Recent advancements
in dehydrogenative cross coupling reactions for CC bond formation . Tetrahedron Lett. 
2017 , 58 , 803 –824 . 10.1016/j.tetlet.2017.01.035 . e Li C.-J. 
Cross-dehydrogenative coupling (CDC): exploring C–C
bond formations beyond functional group transformations . Acc. Chem. Res. 
2009 , 42 , 335 –344 . 10.1021/ar800164n .19220064 
Stuart D. R. ; Fagnou K. 
The Catalytic Cross-Coupling
of Unactivated Arenes . Science 
2007 , 316 , 1172 –1175 . 10.1126/science.1141956 .17525334 
Liu W. ; Yu X. ; Li C. ; Kuang C. 
Palladium-catalyzed
oxidative CH/CH
cross-coupling of pyridine N-oxides with five-membered
heterocycles . Chem. Commun. 
2014 , 50 , 9291 –9294 . 10.1039/C4CC04129A .
a Cho S. H. ; Hwang S. J. ; Chang S. 
Palladium-Catalyzed
C–H Functionalization of Pyridine N-Oxides:
Highly Selective Alkenylation and Direct Arylation with Unactivated
Arenes . J. Am. Chem. Soc. 
2008 , 130 , 9254 –9256 . 10.1021/ja8026295 .18582040  b Roudesly F. ; Veiros L. F. ; Oble J. ; Poli G. 
Pd-Catalyzed Direct
C–H Alkenylation and Allylation of Azine N-Oxides . Org. Lett. 
2018 , 20 , 2346 –2350 . 10.1021/acs.orglett.8b00689 .29629776 
Ackermann L. ; Vicente R. ; Kapdi A. R. 
Transition-metal-catalyzed
direct
arylation of (hetero)arenes by C–H bond cleavage . Angew. Chem., Int. Ed. 
2009 , 48 , 9792 –9826 . 10.1002/anie.200902996 .
Kirilyuk I. A. ; Grigor’ev I. A. ; Volodarskii L. B. 
Synthesis of 2H-imidazole
1-oxides and stable nitroxyl radicals based on them . Russ. Chem. Bull. 
1991 , 40 , 1871 –1879 . 10.1007/BF00960421 .

